TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01168791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin in combination with palifosfamide-tris
Description: palifosfamide-tris: 150 mg/m2 3 days every 21 days for a maximum of 6 cycles.~doxorubicin: 75 mg/m2 1 day every 21 days for a maximum of 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin in combination with placebo
Description: doxorubicin: 75 mg/m2 of doxorubicin 1 day every 21 days for a maximum of 6 cycles.~placebo: 250 mL of normal saline 3 days every 21 days for a maximum of 6 cycles.
Study: NCT02042053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Study: NCT00041483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anecortave Acetate 15 mg sterile suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anecortave Acetate 15 mg sterile suspension

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy (PDT)
Study: NCT02189759

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Kangaroo Mother Care to discharge
Description: Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
Study: NCT03632876

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: retinyl palmitate
Description: The intervention is a daily vitamin A supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: retinyl palmitate
Description: The intervention is a daily vitamin A supplement.
Study: NCT03510169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoVest
Description: Negative pressure ventilation with NeoVest
Study: NCT03488043

Intervention type: PROCEDURE
Intervention: Needle lung biopsy
Description: Needle lung biopsy

Intervention type: PROCEDURE
Intervention: Needle lung biopsy
Description: Needle lung biopsy
Study: NCT04696900

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise training
Description: exercise training in an approved rehabilitation program
Study: NCT04639999

Intervention type: OTHER
Intervention: Echocardiography
Description: LV vortex flow in Echocardiography
Study: NCT05554549

Intervention type: OTHER
Intervention: Dietary pattern observed
Description: Dietary pattern: regular meat-eater, occasional meat-eater, pescatarian, and vegetarian. There are no interventions in this observational cohort.
Study: NCT04205799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
Study: NCT01991275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The intravenous patient-controlled analgesia
Description: The intravenous injection of morphine using the patient-controlled analgesia machine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The intravenous patient-controlled analgesia
Description: The intravenous injection of morphine using the patient-controlled analgesia machine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The intrathecal morphine injection
Description: A single injection of morphine intrathecally
Study: NCT02457806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: Active Spray with deliverable volume of 0.1 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: Active Spray with deliverable volume of 0.1 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: Active Spray with deliverable volume of 0.1 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo spray
Description: Aqueous solution to deliver 0.1 mL per unit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo spray
Description: Aqueous solution to deliver 0.1 mL per unit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spray
Description: Aqueous solution to deliver 0.1 mL per unit
Study: NCT03194568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Vertebral Tether
Description: Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
Study: NCT00041483

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy (PDT)
Study: NCT02056314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic tutorial
Description: The electronic tutorial will provide information to the participants about the nature of gambling, and how to protect themselves against the risks of problem gambling including information on coping skills, and myths associated with gambling.
Study: NCT00219466

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Oxide Diaper Rash Ointment
Description: Desitin Original at diaper change

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aloe Vera/Tocopherol/Zinc Oxide Cream
Description: Desitin Creamy at diaper change
Study: NCT04000399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRITEPath
Description: BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
Study: NCT03473041

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid sling
Description: sling formed of surgeon tailored autologous rectus sheath and polypropylene arms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-O
Description: midurethral transobturator vaginal tape
Study: NCT04074252

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lofstrand Crutches
Description: Device: Set of Lofstrand Crutches

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Crutches
Description: Device: Set of Axillary Crutches
Study: NCT01662505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Patient to receive volasertib
Study: NCT04458792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraffin tissue samples
Description: Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery radiotherapy toxicity : Blood samples collected before the radiotherapy
Study: NCT01406444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhIGF-1
Description: Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Risedronate 35mg PO one time weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Risedronate 35mg PO one time weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly
Study: NCT00580580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optison
Description: 0.1-0.4 mL through intravenous injection at the beginning of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Definity
Description: intravenous injection at 0.05-0.20 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PESDA
Description: intravenous injections dosage 0.05-0.20 mL
Study: NCT04627324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The smart toothbrush and smart mirror (STM) system (XiuSolution, Gyeonggi-do, Korea)
Description: The STM system comprises a smart mirror, which is integrated into a computer monitor, and a 3D motion-capture device inside of a modified toothbrush holder. The computer program displays a toothbrushing animation in the mirror. Toothbrush motions detected by sensors embedded inside the holder are captured and sent to the server for analysis.~(used only during the test visits)~Participants had to brush their teeth at home (using toothbrushes with a flat-trimmed nylon bristle of identical type and length.) for 3 min thrice daily, after meals, as recommended by the Korean Dental Association.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional toothbrush
Description: toothbrushes with a flat-trimmed nylon bristle of identical type and length.~Participants had to brush their teeth at home for 3 min thrice daily, after meals, as recommended by the Korean Dental Association.
Study: NCT01827774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis® Soft Tissue Graft
Description: Surgisis® Soft Tissue Graft for pelvic organ prolapse repair
Study: NCT01011491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medifast 5 & 1 Plan for weight loss and weight maintenance
Description: Medifast's 5 \& 1 Plan is a meal replacement program for weight loss that uses 5 Medifast meals and 1 self-prepared meal. The weight maintenance plan incorporates 3-5 Medifast meals as well as a certain amount of food from all other food groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food-based diet plan for weight loss and weight maintenance
Description: The food-based group was provided a meal plan for weight loss based on the guidelines of the USDA Food Guide Pyramid providing the same number of calories as the Medifast 5 \& 1 Plan. Weight maintenance calories were calculated and participants were provided meal plans from the USDA Food Guide Pyramid.
Study: NCT03822312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBT-TOBI
Description: The DBT-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-TOBI
Description: The MRI-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through. The MRI scan is completed at the same time as the TOBI scan. Participation in this part of the intervention is optional.
Study: NCT02056314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brochure
Description: The brochure is the current means of informing people about the risks of problem gambling. It includes information about problem gambling and help resources.
Study: NCT01714635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis Multifocal Intraocular Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis Multifocal Intraocular Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal Intraocular Lens
Study: NCT02601508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Continuous infusion of rocuronium for PTC 1 + Sugammadex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cis-atracurium
Description: Intermittent injection of cis-atracurium for TOF 1 + Pyridostigmine \& Glycopyrrolate
Study: NCT01917474

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low lipid diet
Description: Patients will receive a diet of about 2000 kcal daily with no more than 20 % of the total energy coming from lipids, mainly from the monounsaturated olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low lipid diet
Description: Patients will receive a diet of about 2000 kcal daily with no more than 20 % of the total energy coming from lipids, mainly from the monounsaturated olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: normal lipid diet
Description: Patients will receive a diet of about 2000 kcal daily with 28 % of the total energy coming from lipids, mainly from the monounsaturated olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: normal lipid diet
Description: Patients will receive a diet of about 2000 kcal daily with 28 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
Study: NCT01782495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet
Study: NCT02645110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MC Hand Soap
Description: Washing hand with soap in comparison to hand washing with water alone

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tap water
Description: Washing hand with water alone in comparison to hand washing with soap
Study: NCT00790855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Starting dose of 50 mg/m\^2 through a needle or catheter in vein over 2 hours twice on Days 1-4 of every 4 week study cycle. A new study cycle may begin when blood cell counts have returned to an appropriate level or a new study cycle may begun earlier if disease gets worse or does not improve.
Study: NCT00303277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvastatin 40 mg tablets once per day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin
Description: pravastatin 80 mg tablets once per day for 12 weeks
Study: NCT01092611

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood collection
Description: Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood collection
Description: Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GSK HIV vaccine 732462
Description: No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies.
Study: NCT02385552

Intervention type: BEHAVIORAL
Intervention: Feedback
Description: Experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rates.
Study: NCT00576108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD7040 Topical Gel
Description: KD7040 topical gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel
Study: NCT02173314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAFE FC
Description: SAFE - FC, a combination of SAFE (developed by ACTION for Child Protection) and Family Connections (developed by Ruth H. Young Center for Families and Children, University of Maryland School of Social Work) for Populations 1 and 2.
Study: NCT00999323

Intervention type: DEVICE
Intervention: stent implantation in coronary artery
Description: Percuatenous Coronary Intervention with implanatation of a stent
Study: NCT00229723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib (Iressa)
Description: 250 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib (Iressa)
Description: 250 mg oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gefitinib (Iressa)
Description: 250 mg oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: intravenous infusion
Study: NCT06386250

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional block
Description: In group A, iliohypogastric and ilioinguinal nerves were blocked by using 0.25% bupivacaine 2ml/kg of combined with skin infiltration of adrenaline 1:200 000.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional block
Description: In group A, iliohypogastric and ilioinguinal nerves were blocked by using 0.25% bupivacaine 2ml/kg of combined with skin infiltration of adrenaline 1:200 000.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional block
Description: In group A, iliohypogastric and ilioinguinal nerves were blocked by using 0.25% bupivacaine 2ml/kg of combined with skin infiltration of adrenaline 1:200 000.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: In group B 0.25% bupivacaine 0.5ml/Kg was infiltrated at the surgical site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: In group B 0.25% bupivacaine 0.5ml/Kg was infiltrated at the surgical site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal block
Description: In group B 0.25% bupivacaine 0.5ml/Kg was infiltrated at the surgical site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: In group C 0.25% Bupivacaine 1ml /kg was given into epidural space at L4-L5 or L5-S1.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: In group C 0.25% Bupivacaine 1ml /kg was given into epidural space at L4-L5 or L5-S1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural
Description: In group C 0.25% Bupivacaine 1ml /kg was given into epidural space at L4-L5 or L5-S1.
Study: NCT04742296

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: low level laser therapy
Description: We will use laser light that has continuous wave mode, power of 100 mW, energy density of 7,5 joule/cm2, treatment time as 300 seconds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy
Description: We will use laser light that has continuous wave mode, power of 100 mW, energy density of 7,5 joule/cm2, treatment time as 300 seconds.
Study: NCT03236974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Arm - Fulvestrant
Description: 500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock
Study: NCT00229723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: intravenous infusion
Study: NCT03236974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9496
Description: Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy
Study: NCT00905398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 400mg, Oral, Bid, Daily for three years
Study: NCT05573789

Intervention type: GENETIC
Intervention: Tumor molecular profiling
Description: Tumor molecular profiling was assessed using the ForeSENTIA® Prostate panel developed by NIPD Genetic
Study: NCT04740502

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Parahtyroidectomy
Description: Parathyroidectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Parahtyroidectomy
Description: Parathyroidectomy
Study: NCT01745172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid body excision
Description: This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation.